Phathom Pharmaceuticals, Inc. (PHAT) is a late clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel treatments for gastrointestinal diseases. It was founded in 2018 and has been publicly traded on the New York Stock Exchange (NYSE) under the ticker "PHAT" since October 2019. The company's primary focus lies in treating health conditions that are in dire need of improved therapy options, striving to elevate the standard of care and enhance patients' quality of life.
The company's lead product is Vonoprazan, an oral potassium-competitive acid blocker (P-CAB), a type of medicine that helps decrease the amount of acid produced by the stomach, with distinct characteristics that mark it out in the acid reflux disease marketplace. Phathom holds exclusive rights to develop and market Vonoprazan in the United States, Europe, and Canada under a licensing agreement with Takeda Pharmaceutical Company. Vonoprazan is currently under Phase 3 trials and being evaluated for erosive esophagitis, a condition that involves the inflammation of the esophagus, and for use in the treatment of Helicobacter pylori (H. pylori) infection, a common chronic bacterial infection of the stomach lining and underlying mucosa which can contribute to the development of certain types of stomach cancer.
Phathom Pharmaceuticals is headquartered in Florham Park, New Jersey, with a corporate office in Buffalo Grove, Illinois. The company has brought together a highly experienced team of professionals from the biopharmaceutical industry to guide its growth and development. As of 2021, it also boasts a strategic partnership with EA Pharma, a gastroenterology-focused pharmaceutical company in Japan, to co-develop Vonoprazan in select Asian markets.
Despite being a young company, Phathom Pharmaceuticals has shown strong potential, particularly in dealing with gastrointestinal diseases. Its robust approach to developing safe and efficient medications aims to revolutionize the healthcare market and provide meaningful solutions for patients suffering from gastrointestinal diseases. As it progresses towards the commercial introduction of its leading candidate, Vonoprazan, the company is poised to make significant contributions to the medical field.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) is showing weak sentiment across all horizons, supporting a short bias according to AI models. The analysis identifies a mid-channel oscillation pattern and an exceptional 81.0:1 risk-reward setup. Three distinct trading strategies are proposed, including position, momentum breakout, and risk hedging, each with specific entry, target, and stop-loss parameters.
Phathom Pharmaceuticals (NASDAQ: PHAT) reported a significant increase in Q3 2026 net product revenue to $84.7 million, up from $49.5 million in Q3 2025. The company also reduced its net loss to $13.9 million in Q3 2026, compared to $29.9 million in the prior-year period. For the first nine months of 2026, net product revenue reached $217.3 million, and the net loss narrowed to $61.8 million.
Phathom Pharmaceuticals reported a significant 71% year-over-year increase in net revenues for Q3 2026, reaching $84.7 million, and achieved its second consecutive quarter of positive operating profit excluding stock-based compensation. The company maintained its full-year revenue guidance and is actively implementing "Access First" initiatives to improve physician prescribing and patient access to Voquezna, including a new $0 copay offering through BlinkRx. Phathom is also progressing with development programs for EoE and non-erosive GERD, while vigorously defending Voquezna's exclusivity period amidst ongoing litigation.
Phathom Pharmaceuticals (PHAT) reported Q3 earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.07, though this was an improvement from a $0.15 loss a year ago. The company's revenues for the quarter were $84.72 million, also falling short of the Zacks Consensus Estimate by 1.71%. Despite mixed estimate revisions ahead of the report, the stock currently holds a Zacks Rank #3 (Hold).
Phathom Pharmaceuticals is facing an FDA review of the exclusivity for its drug VOQUEZNA, following a legal challenge by BDR Pharmaceuticals. The FDA has opened a public docket to gather comments on the legal and regulatory questions surrounding VOQUEZNA's 10-year New Chemical Entity exclusivity, which Phathom believes extends until May 3, 2032. Phathom intends to defend its exclusivity rights through public comments to the FDA and by intervening in BDR's ongoing lawsuit, which could impact the timing of generic competition.